Xbp1, cd138, and cs1 peptides

Abstract

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in WIC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

1 .- 128 . (canceled) 
     
     
         129 . A method for inducing an immune response in a subject, the method comprising administering to the subject a composition comprising:
 (a) a first XBP-1 peptide comprising: (i) the amino acid sequence of SEQ ID NO:6, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO: 6, which, if present, are amino acids that flank SEQ ID NO: 2 in non-spliced XBP1, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO: 6, which, if present, are amino acids that flank SEQ ID NO: 2 in non-spliced XBP1;   (b) a second XBP-1 peptide comprising: (i) the amino acid sequence of SEQ ID NO:10, and (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO: 10, which, if present, are amino acids that flank SEQ ID NO: 9 in spliced XBP1; and   (c) a CD138 peptide comprising: (i) the amino acid sequence of SEQ ID NO:12, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO: 12, which, if present, are amino acids that flank SEQ ID NO: 12 in CD138, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO: 12, which, if present, are amino acids that flank SEQ ID NO: 12 in CD138.   
     
     
         130 . The method of  claim 129 , wherein:
 (a) the first XBP-1 peptide comprises 0 to up to 5 amino acids immediately N-terminal of SEQ ID NO: 6, which, if present, are amino acids that flank SEQ ID NO: 2 in non-spliced XBP1, and 0 to up to 5 amino acids immediately C-terminal of SEQ ID NO: 6, which, if present, are amino acids that flank SEQ ID NO: 2 in non-spliced XBP1;   (b) the second XBP-1 peptide comprises 0 to up to 5 amino acids immediately N-terminal of SEQ ID NO: 10, which, if present, are amino acids that flank SEQ ID NO: 9 in spliced XBP1; and   (c) the CD138 peptide comprises 0 to up to 5 amino acids immediately N-terminal of SEQ ID NO: 12, which, if present, are amino acids that flank SEQ ID NO: 12 in CD138, and 0 to up to 5 amino acids immediately C-terminal of SEQ ID NO: 12, which, if present, are amino acids that flank SEQ ID NO: 12 in CD138.   
     
     
         131 . The method of  claim 129 , wherein the composition comprises a first XBP-1 peptide consisting of the amino acid sequence of SEQ ID NO: 6. 
     
     
         132 . The method of  claim 129 , wherein the composition comprises a second XBP-1 peptide consisting of the amino acid sequence of SEQ ID NO: 10. 
     
     
         133 . The method of  claim 129 , wherein the composition comprises a CD138 peptide consisting of the amino acid sequence of SEQ ID NO: 12. 
     
     
         134 . The method of  claim 129 , wherein the composition further comprises a pharmaceutically acceptable carrier. 
     
     
         135 . The method of  claim 129 , wherein the composition further comprises one or more agents selected from the group consisting of therapeutic agents, diagnostic agents, prophylactic agents, and immunostimulatory agents. 
     
     
         136 . The method of  claim 135 , wherein the one or more agents comprises an immunostimulatory agent. 
     
     
         137 . The method of  claim 129 , wherein the composition further comprises:
 (d) a CS-1 peptide comprising: (i) the amino acid sequence of SEQ ID NO: 16, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO: 16, which, if present, are amino acids that flank SEQ ID NO: 16 in CS-1, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO: 16, which, if present, are amino acids that flank SEQ ID NO: 16 in CS-1.   
     
     
         138 . The method of  claim 129 , wherein the composition further comprises:
 (d) a CS-1 peptide comprising: (i) the amino acid sequence of SEQ ID NO: 16, (ii) 0 to up to 5 amino acids immediately N-terminal of SEQ ID NO: 16, which, if present, are amino acids that flank SEQ ID NO: 16 in CS-1, and (iii) 0 to up to 5 amino acids immediately C-terminal of SEQ ID NO: 16, which, if present, are amino acids that flank SEQ ID NO: 16 in CS-1.   
     
     
         139 . The method of  claim 129 , wherein the composition further comprises:
 (d) a CS-1 peptide consisting of the amino acid sequence of SEQ ID NO: 16.   
     
     
         140 . The method of  claim 129 , wherein the subject has or is at risk of having multiple myeloma or Waldenstrom's macroglobulinemia. 
     
     
         141 . The method of  claim 129 , wherein the subject expresses HLA-A2. 
     
     
         142 . The method of  claim 129 , wherein the subject is a human. 
     
     
         143 . A composition comprising:
 (a) a first XBP-1 peptide comprising: (i) the amino acid sequence of SEQ ID NO:6, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO: 6, which, if present, are amino acids that flank SEQ ID NO: 2 in non-spliced XBP1, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO: 6, which, if present, are amino acids that flank SEQ ID NO: 2 in non-spliced XBP1; or   (b) a second XBP-1 peptide comprising: (i) the amino acid sequence of SEQ ID NO:10, and (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO: 10, which, if present, are amino acids that flank SEQ ID NO: 9 in spliced XBP1.   
     
     
         144 . The composition of  claim 143 , wherein the first XBP-1 peptide consists of the amino acid sequence of SEQ ID NO: 6. 
     
     
         145 . The composition of  claim 143 , wherein the second XBP-1 peptide consists of the amino acid sequence of SEQ ID NO: 10. 
     
     
         146 . A composition comprising a CS-1 peptide comprising: (i) the amino acid sequence of SEQ ID NO: 16, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO: 16, which, if present, are amino acids that flank SEQ ID NO: 16 in CS-1, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO: 16, which, if present, are amino acids that flank SEQ ID NO: 16 in CS-1. 
     
     
         147 . The composition of  claim 146 , wherein the CS-1 peptide comprises: (i) the amino acid sequence of SEQ ID NO: 16, (ii) 0 to up to 5 amino acids immediately N-terminal of SEQ ID NO: 16, which, if present, are amino acids that flank SEQ ID NO: 16 in CS-1, and (iii) 0 to up to 5 amino acids immediately C-terminal of SEQ ID NO: 16, which, if present, are amino acids that flank SEQ ID NO: 16 in CS-1. 
     
     
         148 . The composition of  claim 146 , wherein the CS-1 peptide consists of the amino acid sequence of SEQ ID NO: 16.